@article{oai:kanazawa-u.repo.nii.ac.jp:00013343,
 author = {Zoshima, Takeshi and Matsumura, Masami and Suzuki, Yasunori and Kakuchi, Yasushi and Mizushima, Ichiro and Fujii, Hiroshi and Yamada, Kazunori and Yamagishi, Masakazu and Kawano, Mitsuhiro},
 issue = {5},
 journal = {Modern Rheumatology},
 month = {Sep},
 note = {We describe a patient with refractory cutaneous polyarteritis nodosa (CPAN) with hepatitis B virus (HBV) carrier status who was successfully treated with tumor necrosis factor alpha (TNF-α) blockade, using etanercept, and we review 5 similar cases. We administered etanercept because of the occurrence of repeated flares despite aggressive therapy. C-reactive protein normalization; prednisolone dose-sparing; and absence of any adverse events, including HBV reactivation with nucleotide analogue administration, or renal dysfunction, have been achieved for 8 months. TNF-α blockade should be considered for intractable CPAN. © 2012 Japan College of Rheumatology., In Press →　出版者照会後に全文を公開.},
 pages = {1029--1033},
 title = {A case of refractory cutaneous polyarteritis nodosa in a patient with hepatitis B carrier status successfully treated with tumor necrosis factor alpha blockade},
 volume = {23},
 year = {2013}
}